Zenagamtide
Sources
registry, as of 2026-09-28Stale
https://clinicaltrials.gov/study/NCT07720271
Protocol section, NCT07720271 AMAZE 9, last update posted 2026-09-28
registry, as of 2026-10-06Stale
https://clinicaltrials.gov/study/NCT07861100
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 8500. Conditions Cardiovascular Risk; Obesity. This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo. The purpose of this clinical study is to find out if zenagamtide is safe and
ClinicalTrials.gov NCT07861100 protocol and results modules
registry, as of 2026-08-24Stale
https://clinicaltrials.gov/study/NCT07668401
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 400. Conditions Obesity; Overweight. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatme
ClinicalTrials.gov NCT07668401 protocol and results modules
registry, as of 2026-10-07Stale
https://clinicaltrials.gov/study/NCT07815067
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 320. Conditions Overweight; Obesity. The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.
ClinicalTrials.gov NCT07815067 protocol and results modules
registry, as of 2026-10-16Stale
https://clinicaltrials.gov/study/NCT07868354
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 60. Conditions Overweight; Obesity; Type 2 Diabetes. The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.
ClinicalTrials.gov NCT07868354 protocol and results modules
registry, as of 2026-10-16Stale
https://clinicaltrials.gov/study/NCT07855133
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 60. Conditions Overweight; Obesity; Type 2 Diabetes. The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.
ClinicalTrials.gov NCT07855133 protocol and results modules